Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | CLL & CAR-T: the intricacies and potential

David Maloney • 14 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Leukemia CAR-T Ibrutinib JCAR014 JCAR017

David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the use of CAR T-cell therapy in chronic lymphocytic leukemia (CLL) and the potential of the treatment at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from David Maloney

T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions 12:26
T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions
Alexey Danilov et al. • 11 Apr 2025
Expanding the CAR platform in NHL
David Maloney et al. • 17 Oct 2023
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more… 14:23
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
David Maloney et al. • 30 Apr 2022
Advances in CAR-T therapy for lymphoma 10:21
Advances in CAR-T therapy for lymphoma
Caron Jacobson et al. • 1 May 2022

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals